Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
Kerdpanich P, Chanthavanich P, De Los Reyes MR, Lim J, Yu D, Ama MC, Mojares Z, Casula D, Arora AK, Pellegrini M. Kerdpanich P, et al. Among authors: chanthavanich p. PLoS Negl Trop Dis. 2018 Jun 6;12(6):e0006340. doi: 10.1371/journal.pntd.0006340. eCollection 2018 Jun. PLoS Negl Trop Dis. 2018. PMID: 29874228 Free PMC article. Clinical Trial.
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly.
Frey SE, Shakib S, Chanthavanich P, Richmond P, Smith T, Tantawichien T, Kittel C, Jaehnig P, Mojares Z, Verma B, Kanesa-Thasan N, Hohenboken M. Frey SE, et al. Among authors: chanthavanich p. Open Forum Infect Dis. 2019 Mar 1;6(4):ofz107. doi: 10.1093/ofid/ofz107. eCollection 2019 Apr. Open Forum Infect Dis. 2019. PMID: 30968056 Free PMC article.
A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine.
Pengsaa K, Limkittikul K, Sabchareon A, Ariyasriwatana C, Chanthavanich P, Attanath P, Malerczyk C. Pengsaa K, et al. Among authors: chanthavanich p. Pediatr Infect Dis J. 2009 Apr;28(4):335-7. doi: 10.1097/INF.0b013e3181906351. Pediatr Infect Dis J. 2009. PMID: 19333080 Clinical Trial.
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N. Sabchareon A, et al. Among authors: chanthavanich p. Am J Trop Med Hyg. 2002 Mar;66(3):264-72. doi: 10.4269/ajtmh.2002.66.264. Am J Trop Med Hyg. 2002. PMID: 12139219 Clinical Trial.
One year booster vaccination with purified vero cell rabies vaccine.
Suntharasamai P, Chanthavanich P, Supanaranond W, Warrell MJ. Suntharasamai P, et al. Among authors: chanthavanich p. Trans R Soc Trop Med Hyg. 1988;82(4):633. doi: 10.1016/0035-9203(88)90539-1. Trans R Soc Trop Med Hyg. 1988. PMID: 3256120 No abstract available.
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N. Sabchareon A, et al. Among authors: chanthavanich p. Pediatr Infect Dis J. 2004 Feb;23(2):99-109. doi: 10.1097/01.inf.0000109289.55856.27. Pediatr Infect Dis J. 2004. PMID: 14872173 Clinical Trial.
96 results